• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Angioblast Systems

edit

Angioblast Systems, Inc., a biotechnology company, engages in the development and commercialization of therapeutic products for the treatment of cardiovascular diseases. It provides adult stem cells, protein therapeutics, gene silencing, small molecule peptides and antibodies, cytokines and antigen-receptor inhibitors, and DNAzymes, as well as MPC products for heart failure, heart attacks, peripheral artery diseases, and wound ulcers. The company has a strategic alliance with Mesoblast Limited. Angioblast Systems, Inc. was founded in 2001 and is headquartered in New York, New York.

Recent Milestones

edit

• 
  Angioblast Systems was acquired by Mesoblast. (5/12/10)
  Posted 5/12/10 at 5:34pm via fiercebiotech.com
• 
  Angioblast Systems added Elliott Bendrihem as CFO. (3/18/96)
  Posted 5/12/10 at 5:14pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 5/13/10

Sources

1. Mesoblast to acquire Angioblast and speed up stem cell work (fiercebiotech.com) [edit]